Edwards Lifesciences EW · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
104.71
+2.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$6.07bn
FY2016FY2025
Net income
$1.07bn
FY2016FY2025
Free cash flow
$1.33bn
FY2016FY2025
Shareholders' equity
$10.34bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07bn | $5.44bn | $6.00bn | $5.38bn | $5.23bn | $4.39bn | $4.35bn | $3.72bn | $3.44bn | $2.96bn |
| Gross profit | $4.74bn | $4.32bn | $4.63bn | $4.22bn | $4.01bn | $3.29bn | $3.19bn | $2.80bn | $2.55bn | $2.16bn |
| Research and development | $1.08bn | $1.05bn | $1.07bn | $945.2m | $903.1m | $760.7m | $752.7m | $622.2m | $552.6m | $442.2m |
| Operating income | $1.64bn | $1.38bn | $1.53bn | $1.70bn | $1.61bn | $1.30bn | $1.20bn | $1.09bn | $1.01bn | $815.5m |
| Net income | $1.07bn | $4.17bn | $1.40bn | $1.52bn | $1.50bn | $823.4m | $1.05bn | $722.2m | $622.1m | $569.5m |
| Diluted earnings per share | 1.85 | 7.07 | 2.31 | 2.47 | 2.38 | 1.30 | 1.64 | 1.13 | 0.96 | 0.87 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.70bn | $13.06bn | $9.36bn | $8.29bn | $8.50bn | $7.24bn | $6.49bn | $5.32bn | $5.70bn | $4.51bn |
| Cash and short-term investments | $4.23bn | $3.98bn | $1.63bn | $1.22bn | $1.47bn | $1.40bn | $1.52bn | $956.5m | $1.34bn | $1.27bn |
| Total liabilities | $3.36bn | $2.99bn | $2.64bn | $2.49bn | $2.67bn | $2.66bn | $2.34bn | $2.18bn | $2.70bn | $1.89bn |
| Debt | $622.8m | $597.7m | $597.0m | $596.3m | $595.7m | $595.0m | $594.4m | $593.8m | $1.04bn | $822.3m |
| Shareholders' equity | $10.34bn | $10.00bn | $6.65bn | $5.81bn | $5.84bn | $4.57bn | $4.15bn | $3.14bn | $2.99bn | $2.62bn |
| Shares outstanding | 582m | 591m | 607m | 616m | 632m | 632m | 638m | 637m | 646m | 654m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $1.60bn | $542.3m | $895.8m | $1.22bn | $1.73bn | $1.05bn | $1.18bn | $926.8m | $1.00bn | $704.4m |
| Capital spending | −$260.2m | −$252.4m | −$266.3m | −$264.8m | −$329.8m | −$407.3m | −$278.4m | −$241.7m | −$175.5m | −$217.4m |
| Free cash flow | $1.33bn | $289.9m | $629.5m | $953.4m | $1.40bn | $647.0m | $901.0m | $685.1m | $825.2m | $487.0m |
| Dividends paid | — | — | −$169.9m | −$146.4m | −$158.6m | −$140.5m | −$18.9m | −$688.0m | — | −$253.5m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74bn | $1.65bn | $1.57bn | $1.55bn | $1.53bn | $1.41bn | $1.39bn | $1.35bn |
| Gross profit | $1.35bn | $1.29bn | $1.23bn | $1.21bn | $1.19bn | $1.11bn | $1.09bn | $1.09bn |
| Operating income | $519.5m | $514.7m | $370.3m | $425.1m | $430.9m | $394.8m | $312.6m | $350.6m |
| Net income | $241.9m | $380.7m | $91.2m | $291.1m | $329.8m | $358.0m | $385.6m | $3.07bn |
| Diluted earnings per share | 0.42 | 0.66 | 0.16 | 0.50 | 0.57 | 0.62 | 0.65 | 5.20 |
| Cash from operations | $651.0m | $43.0m | $450.0m | $573.0m | $290.0m | $280.0m | $280.0m | $351.0m |
| Capital spending | −$66.0m | −$64.0m | −$97.0m | −$57.0m | −$49.0m | −$56.0m | −$56.0m | −$31.0m |
| Free cash flow | $585.0m | −$21.0m | $353.0m | $516.0m | $241.0m | $224.0m | $224.0m | $320.0m |
| Total assets | $13.87bn | $13.32bn | $13.70bn | $13.27bn | $13.49bn | $13.02bn | $13.06bn | $12.97bn |
| Cash and short-term investments | $4.25bn | $3.67bn | $4.23bn | $3.84bn | $4.06bn | $3.90bn | $3.98bn | $4.45bn |
| Debt | $622.8m | $622.8m | $622.8m | $625.0m | $623.9m | $621.5m | $621.1m | $621.7m |
| Shareholders' equity | $10.62bn | $10.33bn | $10.34bn | $10.21bn | $10.55bn | $10.13bn | $10.00bn | $9.55bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 4.1% | 6.7% | 9.3% |
| Operating income | -1.3% | 4.8% | 11.0% |
| Net income | -11.0% | 5.4% | 8.1% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 78.8% | 78.2% | 77.5% | 76.2% |
| Operating margin | 26.2% | 27.3% | 28.2% | 28.0% |
| Net margin | 45.6% | 35.7% | 32.3% | 28.2% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 46.2 | 10.5 | 33.0 | 30.2 | 54.5 | 70.0 | 47.4 | 45.0 | 39.0 | 35.9 |
| Price to sales | 8.2 | 8.0 | 7.7 | 8.5 | 15.7 | 13.1 | 11.4 | 8.7 | 7.1 | 6.9 |
Market value over time
31 Oct 2016 to 18 Sept 2026, in USD
$20.76bn$50.98bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 16% | -3% | 3% | -39% | 40% | 9% | 59% | 30% | 26% | 15% |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 3-for-1 split · 1 Jun 2020
- 2-for-1 split · 14 Dec 2015
- 2-for-1 split · 28 May 2010
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.